

 <h1 style="margin: 0;">SENDERRA</h1> <p style="margin: 0; font-size: small;">Specialty Pharmacy</p> <p style="margin: 0;">3712 E. Plano Parkway, Ste. 200 Plano, TX 75074</p> <p style="margin: 0; font-size: x-small;">This prescription form is to be sent & received via fax</p>	Oncology Enrollment Form A-D	Prescriber:	NPI:
		Supervising Physician:	NPI:
		Address:	Tax ID:
		Phone:	Fax:
		Contact:	
Physician Offices Call: 877-513-3107		Fax: 855-662-6779	

PATIENT INFORMATION			
Name:	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: ____-____-____
Street:	City:	State:	ZIP:
Phone:	Alt. Phone:	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: ____	Wt.: ____ Ht.: ____

PRESCRIPTION			
<input type="checkbox"/> New <input type="checkbox"/> Refill	Ship by: ____/____/____	SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: ____	
Drug	Directions & Quantity		Refills
Abiraterone acetate	<input type="checkbox"/> 250 mg Tablet	<input type="checkbox"/> Take 1,000 mg (FOUR 250 mg tablets) PO once daily on an empty stomach (Quantity: 120)	
	<input type="checkbox"/> 500 mg Tablet	<input type="checkbox"/> Take 1,000 mg (TWO 500 mg tablets) PO once daily on an empty stomach (Quantity: 60)	
Bexarotene	<input type="checkbox"/> 75 mg Capsule	***BSA Required: ____ m²*** <input type="checkbox"/> Take ____ mg by mouth once daily with food (Quantity: QS 30 days)	***RECOMMENDED DOSING*** 300 mg/m ² /day-taken as one daily dose
	<input type="checkbox"/> 1% Gel 60 gm	INITIAL: Quantity: 1 tube <input type="checkbox"/> Week 1: Apply to affected area(s) once every other day as directed <input type="checkbox"/> Week 2: Apply to affected area(s) once daily as directed <input type="checkbox"/> Week 3: Apply to affected area(s) twice daily as directed <input type="checkbox"/> Week 4: Apply to affected area(s) three times daily as directed <input type="checkbox"/> Week 5: Apply to affected area(s) four times daily as directed MAINTENANCE: <input type="checkbox"/> Apply to affected area(s) ____ times daily as directed (Quantity: 1 tube)	
Capecitabine	<input type="checkbox"/> 150 mg Tablet	***BSA Required: ____ m²***	
	<input type="checkbox"/> 500 mg Tablet	<input type="checkbox"/> Take ____ mg PO twice daily on days 1-14 of a 21 day cycle, then repeat (Quantity: QS for 21 day cycle) <input type="checkbox"/> Take ____ mg PO twice daily for ____ days with ____ days off, then repeat (Quantity: ____)	
Dasatinib	<input type="checkbox"/> 20 mg Tablet	<input type="checkbox"/> Take ____ mg PO once daily (Quantity: ____) ***WEIGHT REQUIRED*** ____	
	<input type="checkbox"/> 50 mg Tablet		
	<input type="checkbox"/> 70 mg Tablet		
	<input type="checkbox"/> 80 mg Tablet		
	<input type="checkbox"/> 100 mg Tablet	<input type="checkbox"/> Take 100 mg PO once daily (Quantity: 30)	
	<input type="checkbox"/> 140 mg Tablet	<input type="checkbox"/> Take 140 mg PO once daily (Quantity: 30)	
Deferasirox	<input type="checkbox"/> 90 mg Tablet	<input type="checkbox"/> Take ____ mg PO once daily (Quantity: ____) ***WEIGHT REQUIRED*** ____	
	<input type="checkbox"/> 180 mg Tablet		
	<input type="checkbox"/> 360 mg Tablet		
Other: ____	____	____ (Quantity: ____)	

MEDICAL INFORMATION			
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY			
PREVIOUS THERAPIES: <input type="checkbox"/> _____ <input type="checkbox"/> _____	Tried & Failed (Duration): <input type="checkbox"/> _____ <input type="checkbox"/> _____	Not Tolerated: <input type="checkbox"/> _____ <input type="checkbox"/> _____	Reason(s) for Discontinuation: _____ _____
Date of Diagnosis: ____/____/____	TNM Stage: _____	Mutation(s) Present: _____	
<input type="checkbox"/> C _____	<input type="checkbox"/> C18.9 Malignant neoplasm of colon, unspecified	<input type="checkbox"/> C50. _____ Malignant neoplasm of breast	<input type="checkbox"/> C61 Malignant neoplasm of prostate
<input type="checkbox"/> C84.A0 Cutaneous T-cell lymphoma, unspecified, unspecified site	<input type="checkbox"/> C84.A ____ Cutaneous T-cell lymphoma, unspecified, _____	<input type="checkbox"/> C91.0 ____ Acute lymphoblastic leukemia (ALL)	<input type="checkbox"/> C92.1 ____ Chronic Myeloid Leukemia, BCR/ABL-positive
<input type="checkbox"/> D56. ____	<input type="checkbox"/> E83.111 Chronic iron overload due to blood transfusions	<input type="checkbox"/> Other: _____	
Additional Clinical Information: _____ _____			

PRESCRIBER SIGNATURE REQUIRED---STAMPED SIGNATURE NOT ALLOWED	
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.	
Prescriber: _____	Date: ____/____/____

CONFIDENTIALITY NOTICE
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.